US-based biotech company Bexion Pharmaceuticals has begun its Phase I trial of BXQ-350 to treat advanced solid tumours.

BXQ-350 is a synthetically produced, anti-neoplastic therapeutic agent featuring Saposin C (sphingolipid activator protein, or SapC) and the phospholipid, dioleoylphosphatidylserine (DOPS), which is based on a patented, nanovesicle formulation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A combination of both components targets cells in a tumour mass and kills them.

The Phase I trial has been designed as an open-label, dose-escalation, first in human study intended to determine the maximum tolerate dose (MTD) of BXQ-350 and its safety when administered as a single agent at escalating doses.

"Dosing our first ever patient with BXQ-350 is a significant milestone for Bexion."

The study will involve adult patients with advanced solid tumours and recurrent high-grade gliomas who will be intravenously infused with BXQ-350.

The secondary goals of the study are to test the preliminary antitumour activity of BXQ-350 in solid tumours and recurrent high-grade gliomas.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bexion founder and CEO Dr Ray Takigiku said: "Dosing our first ever patient with BXQ-350 is a significant milestone for Bexion.

"This trial is designed to study the safety and tolerability of BXQ-350 in patients with advanced solid tumours including glioblastoma multiforme (GBM) and may yield further insights into the potential anti-tumour activity of BXQ-350."

Results of pre-clinical studies conducted on animals have suggested the efficacy of BXQ-350 in inducing cell death within a variety of cancers.